



# COVID-19

## Health Evidence Summary No.56

### summary from this week

Kerry Millington & Samantha Reddin

Liverpool School of Tropical Medicine (LSTM) & Institute of Development Studies

05 June 2020

*This is a weekly summary of the daily COVID-19 health evidence summary (HES) which are based on 3 hours of desk-based research each day. The summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make original documents easily accessible to decision makers which, if relevant to them, they should go to before making decisions.*

### Clinical characteristics and management

Publication date	Title/URL	Journal/Article type	Summary	Keywords
01.06.2020	COVID-19 mortality is associated with pre-existing disease burden: a cross-country analysis	Bulletin WHO   Article	<ul style="list-style-type: none"> <li>• Cross-sectional study of 45 HICs and 42 non-HICs using global burden of disease data</li> <li>• Whilst in HICs C19 mortality was associated with pre-existing disease burden, no association was found between disease burdens and C19 mortality rate for non-HICs</li> </ul>	Mortality, co-morbidity
02.06.2020	Clinical features of COVID-19 patients in Abdul Wahab Sjahranie Hospital, Samarinda, Indonesia	medRxiv   Preprint (not peer reviewed)	<ul style="list-style-type: none"> <li>• The majority of COVID-19 patients are male. COVID-19 comorbidities were found in several patients. The main clinical symptoms of COVID-19 in this study were cough, sore throat, and fever.</li> <li>• The abnormal laboratory finding in</li> </ul>	Morbidity

			<p>COVID-19 patients is anemia, an increase in AST and ALT levels, and chest x-ray images of pneumonia. All patients are in mild condition. The average length of hospital admission patients to discharge is more than 30 days.</p> <ul style="list-style-type: none"> <li>• The inability of a local laboratory to check for positive confirmation of COVID-19 makes the admission period of the patient in the hospital very long. The availability of RT-PCR tests at Abdul Wahab Sjahranie Hospital Samarinda will greatly assist the further management of COVID-19 patients..</li> </ul>	
29.05.2020	<p>Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: A Review</p>	<p>JAMA Neurology   Review</p>	<ul style="list-style-type: none"> <li>• MERS-CoV and SARS-CoV-1 are known to cause disease in the central and peripheral nervous systems</li> <li>• The pulmonary manifestations of C19 have been well described in the literature but emerging evidence suggests C19 has neurologic consequences as well</li> <li>• This review summarises available information regarding neurological disorders associated with C19 which may lead to improved</li> </ul>	<p>Morbidity   Neurological</p>

			clinical outcomes and better treatment algorithms. This review also highlights where further studies are required	
29.05.2020	Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study	The Lancet   Article	<ul style="list-style-type: none"> <li>• Analysis of 1128 patients who had surgery between 1 Jan and 31 Mar 2020</li> <li>• Postoperative pulmonary complications occur in half of patients with perioperative SARS-CoV-2 infection and are associated with high mortality</li> <li>• Thresholds for surgery during the C19 pandemic should be raised compared to normal practice, especially in men aged 70 years and older</li> <li>• Postponing non-urgent procedures and promoting non-operative treatment to delay or avoid the need for surgery should be considered</li> </ul>	Mortality   surgery
29.05.2020	Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study	The Lancet Oncology   Article	<ul style="list-style-type: none"> <li>• Patients with cancer and COVID-19 were more likely to deteriorate into severe illness than those without cancer</li> <li>• Risk factors identified in this study may help early clinical surveillance of disease progression of C19 in patients with cancer</li> </ul>	Morbidity   NCD

29.05.2020	Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study	The Lancet Oncology   Article	<ul style="list-style-type: none"> <li>• Patients with cancer and COVID-19 admitted to hospital had a high case-fatality rate</li> <li>• Unfavourable prognostic factors, including receiving chemotherapy within 4 weeks before symptom onset and male sex, may help clinicians identify patients at high risk of dying</li> </ul>	Mortality   NCD
------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------

## Epidemiology and modelling

Publication date	Title/URL	Journal/Article type	Summary	Keywords
03.06.2020	Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review	Annals of Internal Medicine   Review	<ul style="list-style-type: none"> <li>• It is likely that 40 to 45% of those infected with SARS-CoV-2 will remain asymptomatic – the virus may silently spread more than previously estimated</li> <li>• Asymptomatic persons can transmit SARS-CoV-2 and perhaps longer than 14 days</li> <li>• Absence of symptoms in infected persons might not imply absence of harm. More research is needed to determine the significance of subclinical lung changes</li> <li>• Testing programmes must broaden to include</li> </ul>	Asymptomatic, transmission, testing

			<p>those without symptoms</p> <ul style="list-style-type: none"> <li>• Limitation – most data under review was from cohort studies</li> <li>• It remains difficult to distinguish between asymptomatic and presymptomatic persons</li> </ul>	
02.06.2020	<p>Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: a modelling study</p> <p><i>(Included for possible lessons learnt and projections relevant for LMIC)</i></p>	Lancet   Article	<ul style="list-style-type: none"> <li>• This study assesses the potential impact of different control measures for mitigating the burden of COVID-19 in the UK.</li> <li>• The four base interventions modelled were school closures, physical distancing, shielding of people aged 70 years or older, and self-isolation of symptomatic cases.</li> <li>• Conclusion that intensive interventions with lockdown periods would need to be in place for a large proportion of the coming year to prevent health-care demand exceeding availability.</li> </ul>	Modelling
29.05.2020	<p>Statistical analysis of the impact of environmental temperature on the exponential growth rate of</p>	PLOS One/ Research article	<ul style="list-style-type: none"> <li>• statistical analysis for understanding the effect of the environmental temperature on the exponential growth rate of the cases infected by COVID-19 for US and Italian regions.</li> </ul>	Growth rate

	cases infected by COVID-19		<ul style="list-style-type: none"> <li>The results clearly support the first reported statistically significant relationship of <b>negative</b> correlation between the average environmental temperature and exponential growth rates of the infected cases.</li> </ul>	
30.05.2020	Early transmission of SARS-CoV-2 in South Africa: an epidemiological and phylogenetic report	medRxiv   Preprint (not peer reviewed)	<ul style="list-style-type: none"> <li>A molecular epidemiological study by a network of government and university laboratories of the first 21 SARS-CoV-2 whole genomes sampled in the first port of entry, KwaZulu-Natal (KZN) during the first month of the epidemic</li> <li>The early introduction of SARS-CoV-2 in KZN included a localised hospital outbreak which may explain the initially high death rates in the province</li> <li>The current high rate of transmission of C19 in the Western Cape and Eastern Cape highlights the need to strengthen local genomic surveillance in SA</li> <li></li> </ul>	

## Infection Prevention and Control

Publication date	Title/URL	Journal/Article type	Summary	Keywords
04.06.2020	Correlation between N95 extended use and reuse and fit failure in an emergency department	JAMA   Research Letter	<ul style="list-style-type: none"> <li>• There is a lack of empirical evidence on the effectiveness of N95 reuse and extended use during critical PPE shortages. This study examined the prevalence of N95 fit test failure while reusing 2 common types of N95 masks</li> <li>• Duckbill N95s had a high failure rate. Failure of dome-shaped masks was associated with increased use.</li> <li>• N95 failure may contribute to SARS-CoV-2 transmission and based on this preliminary data, health systems should closely evaluate N95 fit during extended use or reuse and limit duckbill mask use if alternatives are available</li> <li>• Limitations, including the study's cross-sectional design, are noted</li> </ul>	Face masks
04.06.2020	Social network-based distancing strategies to flatten the COVID-19 curve	Nature Human Behaviour   Article	<ul style="list-style-type: none"> <li>• Social, psychological and economic consequences of complete or near-complete lockdown demand more moderate contact-reduction policies</li> </ul>	Social distancing, behaviour, infection control

	in a post-lockdown world		<ul style="list-style-type: none"> <li>• The effectiveness of 3 distancing strategies designed to keep the curve flat and aid compliance post-lockdown are evaluated in this study</li> <li>• Strategic social network-based reduction of contact strongly enhances the effectiveness of social distancing measures while keeping risks lower</li> </ul>	
03.06.2020	Seroprevalence of SARS-CoV-2 in Hong Kong and in residents evacuated from Hubei province China: a multicohort study	The Lancet Microbe   Article	<ul style="list-style-type: none"> <li>• Control measures implemented in Hong Kong and Hubei province successfully restricted the spread of SARS-CoV-2 as of May 2020</li> <li>• Relatively low seroprevalence suggests lack of herd immunity and susceptibility to a resurgence of the SARS-CoV-2 epidemic if public health measures are relaxed</li> <li>• Although a small study size, provides a baseline for public health authorities when evaluating the effect of current and future interventions</li> </ul>	Seroprevalence, transmission, herd immunity
01.06.2020	Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2	The Lancet	<ul style="list-style-type: none"> <li>• Systematic review and meta-analysis to investigate the optimum distance for avoiding person-to-person virus transmission and to assess the use of face masks and eye protection to prevent</li> </ul>	Face masks, eye protection

	and COVID-19: a systematic review and meta-analysis		<p>transmission of viruses.</p> <ul style="list-style-type: none"> <li>• The findings of this systematic review and meta-analysis support physical distancing of 1 m or more and provide quantitative estimates for models and contact tracing to inform policy.</li> <li>• Optimum use of face masks, respirators, and eye protection in public and health-care settings should be informed by these findings and contextual factors.</li> <li>• Robust randomised trials are needed to better inform the evidence for these interventions, but this systematic appraisal of currently best available evidence might inform interim guidance.</li> </ul>	
--	--------------------------------------------------------------	--	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--

## Testing

Publication date	Title/URL	Journal/Article type	Summary	Keywords
04.06.2020	Serodiagnostics for Severe Acute Respiratory Syndrome-Related Coronavirus-2: A narrative review	Annals of Internal Medicine   Review	<ul style="list-style-type: none"> <li>• Discusses key use cases for SARS-CoV-2 antibody detection tests and their application to serologic studies</li> <li>• Reviews currently available assays</li> <li>• Highlights ongoing research</li> <li>• Proposes potential strategies for test implementation</li> </ul>	Serodiagnostics

## Therapeutics

Publication date	Title/URL	Journal/Article type	Summary	Keywords
03.06.2020	A randomised trial of hydroxychloroquine as postexposure prophylaxis for Covid-19	NEJM   Article	<ul style="list-style-type: none"> <li>A randomised, double-blind, placebo-controlled trial across the US and parts of Canada testing hydroxychloroquine as postexposure prophylaxis</li> <li>Hydroxychloroquine did not prevent illness compatible with C19 or confirmed infection when used within 4 days after high-risk or moderate-risk exposure to C19</li> </ul>	RCT, hydroxychloroquine, prophylaxis
03.06.2020	Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomised clinical trial	JAMA   Article	<ul style="list-style-type: none"> <li>In this randomised clinical trial of 103 patients in China that was terminated early (underpowering the study), among patients with severe or life-threatening C19, convalescent plasma therapy added to standard treatment did not significantly improve the time to clinical improvement within 28 days</li> </ul>	RCT, convalescent plasma
02.06.2020	G6PD variant distribution in sub-Saharan Africa and potential risks of using chloroquine/hydroxychloroquine based treatments for COVID-19	medRxiv   Preprint (not peer reviewed)	<ul style="list-style-type: none"> <li>Chloroquine/hydroxychloroquine have been proposed as potential treatments for COVID-19. These drugs have warning labels for use in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Analysis of whole-genome sequence data of 458 individuals from sub-Saharan Africa showed significant G6PD</li> </ul>	Drug, Chloroquine/hydroxychloroquine

			<p>variation across the continent.</p> <ul style="list-style-type: none"> <li>The high prevalence of variants in the G6PD gene found in this analysis suggests that it may be a significant interaction factor in clinical trials of chloroquine and hydrochloroquine for treatment of COVID-19 in Africans.</li> </ul>	
--	--	--	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--

## Indirect impact of COVID-19

Publication date	Title/URL	Journal/Article type	Summary	Keywords
29.05.2020	Rapid assessment of service delivery for NCDs during the COVID-19 pandemic	WHO NCD Department   Preliminary results	<ul style="list-style-type: none"> <li>A survey run by WHO with responses from 155 countries has shown that C19 significantly impacts health services for cancer, cardiovascular disease and diabetes</li> <li>Countries must find innovative ways to continue essential health services</li> </ul>	Health service   NCD

## Social Science

Publication date	Title/URL	Journal/Article type	Summary	Keywords
02.06.2020	Public Knowledge and Practices regarding COVID-19: A cross-sectional survey from Pakistan	medRxiv   Preprint (not peer reviewed)	<ul style="list-style-type: none"> <li>Pakistani residents had good knowledge and practices towards COVID-19 yet there are gaps in specific aspects of knowledge, and practice that should be focused in future awareness and educational campaigns.</li> <li>Study recommends the ministry of health authorities promote all precautionary and preventive measures of COVID-19 - to all strata of</li> </ul>	equity

			society including less privileged people, older ones and less educated people.	
29.05.2020	Initial psychological impact of COVID-19 and its correlates in Indian Community: An online (FEEL-COVID) survey	PLOS one/ research article	<ul style="list-style-type: none"> <li>• From 26th to 29th March an online survey</li> <li>• 1106 responses from around 64 cities in the country</li> <li>• During the initial stages of COVID-19 in India, almost one-third respondents had a significant psychological impact. This indicates a need for more systematic and longitudinal assessment of psychological needs of the population, which can help the government in formulating holistic interventions for affected individuals.</li> </ul>	Mental health
29.05.2020	Behavioural health and response for COVID-19	Disaster Medicine and Public Health Preparedness	<ul style="list-style-type: none"> <li>• Research suggests that behavioural health concerns should take a primary role in response to the pandemic</li> <li>• A four-step services system is proposed designed for implementation with a variety of different groups and reserves limited clinical services for the most extreme reactions</li> </ul>	Behaviour
22.05.2020	COVID-19 pandemic, socioeconomic crises and human stress in resource-limited settings: A case from Bangladesh	Cell   Research Article	<ul style="list-style-type: none"> <li>• Study to understand the public perception of socioeconomic crises and human stress in resource-limited settings of Bangladesh during the C19 outbreak</li> <li>• 1066 Bangladeshi participants</li> </ul>	Mental health

## Comments, Editorials, Opinions, Blogs, News

Publication date	Title/URL	Journal   Article type	Author(s)
05.06.2020	Oxford University's COVID-19 vaccine: next steps towards broad and equitable global access	University of Oxford   News	
04.06.2020	Brazilian Health Regulatory Agency approves trial of Oxford COVID-19 Vaccine	Med Sci University of Oxford   News	
05.06.2020	Retraction – Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis	The Lancet   Comment	Mandeep R Mehra Frank Ruschitzka Amit N Patel
04.06.2020	Retraction: Cardiovascular disease: drug therapy, and mortality in Covid-19. NEJM DOI 10.1056/NEJMoa2007621	NEJM   Correspondence	Mandeep R Mehra Sapan S Desai SreyRam Kuy Timothy D Henry Amit N Patel
04.06.2020	Making decisions in a COVID-19 world	JAMA   Viewpoint	Baruch Fischhoff
04.06.2020	Is Nigeria Ready to leave lockdown?	CGD   Blog	Benjamin Uzochukwu Francis Ruiz Kalipso Chalkidou Eno'bong Idiong Samantha Hollingworth

04.06.2020	India's COVID-19 testing capacity must grow by a factor of 10: here's how that can happen	CGD   Notes	Prashant Yadav Abha Mehndiratta Kalipso Chalkidou Sidharth Rupani Krishna Reddy
04.06.2020	The indirect health effects of COVID-19: lockdown measures and service provision	CGD   Blog	Lydia Regan Y-Ling Chi
03.06.2020	As global health players pivot to COVID-19 responses we need coordinated, real-time, formative evaluations	CGD   Blog	Pippa Page Cassandra Nemzoff Kalipso Chalkidou Sam McPherson
03.06.2020	Hydroxychloroquine for the prevention of COVID-19 – searching for evidence	NEJM   Editorial	Marc DuBois Julian Sheather Catherine R. McGowan Louisa Baxter Rachael Cummings
03.06.2020	Africa's COVID-19 resilience must not lead to complacency	Chatham House   Comment	Dr Knox Chitiyo Prof Martin Rupiya Pamela Wadi
03.06.2020	A randomised trial of convalescent plasma for COVID-19 – potentially hopeful signals	JAMA   Editorial	
03.06.2020	Population serology for SARS-CoV-2 is essential to regional and global preparedness	The Lancet Microbe   Comment	Huaiyu Tian Ottar N Bjornstad

02.06.2020	Global outbreak research: harmony not hegemony	The Lancet Infectious Diseases  Comment	ISARIC clinical characterisation group
02.06.2020	COVID-19 and essential pregnant worker policies	The Lancet Infectious Diseases  Correspondence	Elizabeth S McDonald
02.06.2020	Of viruses, vaccines, and variability: qualitative meaning matters	Trends in Cognitive Sciences	Valerie F. Reyna
28.05.2020	Covid-19 in humanitarian settings: addressing ethics to reduce moral distress	BMJ   Opinion	
02.06.2020	Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis	Lancet   Expression of concern	
June 2020	Initiation of the Global Coalition for Radiotherapy during the COVID-19 pandemic	Lancet Oncology   Comment	Pat Price, Shandi E Barney
02.06.2020	Global mental health and COVID-19	Lancet Psychiatry   Comment	Lola Kola
02.06.2020	The need for privacy with public digital contact tracing during the COVID-19 pandemic	Lancet Digital Health   Comment	Yoshua Bengio, Richard Janda et al
02.06.2020	Thousands of people will help scientists to track the long-term health effects of the coronavirus crisis	Nature  News	
02.06.2020	A Harm-Reduction Approach to Coronavirus Disease 2019	JAMA Health Forum   Insights	Eric Kutscher, Richard E. Greene

	(COVID-19)—Safer Socializing		
26.05.2020	Why Africa struggles to test for covid-19	The Economist   News	
25.05.2020	Complexity and fragility: realising the SDGs in  The face of Covid-19	4SD/ brief	David Nabarro
28.305.2020	Research on covid-19 is suffering “imperfect incentives at every stage”	BMJ/ Blog	Stephen Armstrong
01.06.2020	Obstacles to COVID-19 control in east Africa	Lancet Infectious Diseases/ Newsdesk	Esther Nakkazi
01.06.2020	Food insecurity will be the sting in the tail of COVID-19	Lancet Global Health/ Editorial	
01.06.2020	COVID-19 effect on mental health: patients and workforce	Lancet Psychiatry / Comment	Victor Pereira-Sanchez, Frances Adiukwu et al
01.06.2020	Death threats in Brazil after a trial on chloroquine for COVID-19	Lancet Infectious Diseases/ Newsdesk	Estella Ektorp
30.05.2020	Fears of “highly catastrophic” COVID-19 spread in Yemen	Lancet / World Report	Sharmila Devi
30.05.2020	COVID-19 strains remote regions of Peru	Lancet / World Report	Barbara Fraser
30.05.2020	COVID-19 in Africa: no room for complacency	Lancet/ Editorial	
01.06.2020	Covid-19 hot spots appear across Latin America	BMJ/ News	Owen Dyer

	Comment on “COVID-19 Preparedness Within the Surgical, Obstetric, and Anesthetic Ecosystem in Sub Saharan Africa”	Annals of Surgery/ Letter	Starr, Nichole; Weiser, Thomas
29.05.2020	Facing mental health fallout from the coronavirus pandemic	WHO / News	
01.06.2020	Covid-19 and health: five expert views	ODI   Blog	Emma Samman Tom Hart Fiona Samuels Carmen Leon-Himmelstine Vidya Diwakar
May 2020	Towards universal health systems in the Covid-19 era: opportunities and threats	ODI   Briefing paper	Emma Samman
29.05.2020	All eyes are on local humanitarian responders during Covid-19 – now they need support	ODI   Comment	John Bryant
01.06.2020	COVID-19 significantly impacts health services for noncommunicable diseases	WHO   News release	
29.05.2020	The South African Response to the Pandemic	NEJM   Correspondence	Salim S. Abdool Karim
29.05.2020	The right to health must guide responses to COVID-19	The Lancet   Comment	Dainius Puras Judith Bueno de Mesquita Luisa Cabal Allan Maleche

			Benjamin Mason Meier
29.05.2020	Lockdown poses new challenges for cancer care in India	The Lancet Oncology   News	Dinesh C. Sharma
29.05.2020	Poor clinical outcomes for patients with cancer during the COVID-19 pandemic	The Lancet Oncology   Comment	Liang V Tang Yu Hu
27.05.2020	Tracking the genomic footprints of SARS-CoV-2 transmission	Cell   Spotlight	Tommy Tsan-Yuk Lam

## Guidelines, Statements & Tools

Publication Date	Title/URL	Source	Summary
05.06.2020	Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on hydroxychloroquine	RECOVERY Trial   Statement	<ul style="list-style-type: none"> <li>At the request of the MHRA the independent DMC recommended chief investigators review the unblinded data on the hydroxychloroquine arm of the trial</li> <li>No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19</li> <li>Participants are no longer to be enrolled to the hydroxychloroquine arm of the RECOVERY trial with immediate effect</li> <li>Full results will be made available as soon as possible</li> </ul>
01.06.2020	Maintaining essential health services: operational guidance for the COVID-19 context	WHO   Interim guidance	<ul style="list-style-type: none"> <li>Note an update to interim guidance issues on 25 March 2020</li> <li>Practical actions that countries can take at national, subregional and local levels to reorganise and safely delivery high-quality essential health services in the pandemic context</li> </ul>

			<ul style="list-style-type: none"> <li>Includes sample indicators for monitoring essential health services</li> <li>Describes considerations when to stop and restart services as C19 transmission recedes and surges</li> </ul>
May 2020	COVID-19 Considerations for home and community-based care	SSHAP   Brief	<ul style="list-style-type: none"> <li>Guidelines from LMICs recognise the need for supported home and community-based care for C19 to protect formal healthcare setting capacity and to reduce the risk of spread in health facilities. Moreover, not all will be able to access services or may prefer home care.</li> <li>The Brief reviews existing guidance on home and community-based care for C19 in different contexts, identifies key issues and offers recommendations for addressing gaps in home and community-based care</li> </ul>
01.06.2020	Basic Psychosocial Skills: A Guide for COVID-19 Responders	WHO	<ul style="list-style-type: none"> <li>This Guide aims to help orient people supporting the COVID-19 response to integrate psychosocial support skills into their daily work, thereby making a difference to the well-being of people they come into contact with during the pandemic.</li> <li>The guide advises how to help others find their own solutions to their problems.</li> </ul>

## Dashboards & Trackers

Cases & deaths: Global	Cases & deaths: Regional	Cases & deaths: Country	Living evidence & policy maps	Current research including trials	Diagnostics	Treatments	Vaccines
WHO sitreps	WHO Africa	Ghana	COVID-NMA	WHO	FIND SARS-CoV-2 Test Tracker	Global COVID-19 Clinical Trial Tracker	CEPI

WHO dashboard	African Arguments	Indonesia	EPPI Centre	WHO International Clinical Trials Registry Platform (ICTRP)	FIND SARS-CoV-2 Diagnostics: performance data	US NIH registered clinical trials	Vaccine Centre LSHTM
Johns Hopkins University	European CDC	Nigeria CDC	Norwegian Institute of Public Health	Cytel	Serology-based tests for COVID-19	Solidarity trial	COVID-19 Oxford Vaccine Trial
WEF		Sierra Leone	Oxford COVID-19 Government Response Tracker (OxCGRT)	US NIH	Our World in Data: COVID-19 Testing	COVID-19 Therapeutics Accelerator	
Our World in Data		Singapore	Our World in Data: COVID-19 Policy responses	COVID-evidence			
Global 5050		UK	IFPRI COVID-19 Policy Response Portal	Cochrane			
CEBM, University of Oxford		US	COVID-19 Primer	Clinicaltrials.gov			
Humanitarian Data Exchange			NIH LitCovid	UKCDR			
Information is Beautiful			WHO COVID-19 Database				
LSHTM							

HealthMap (cases)							
The Commons Project							

## C19 Resource Hubs

Global	Regional & Country	Academic journals & Publishers	Institutes/Centres /Funders/Other	Health Topics	Social Sciences
WHO COVID-19 pandemic	Africa CDC	Annals of Internal Medicine	LSTM	Stop TB Partnership	SSHAP
WHO risk communication	African Union	BMJ	LSHTM		IDA
WHO Q&A	Nigeria CDC	Bulletin of the WHO	ICL MRC Centre for Global Infectious Disease Analysis	Global Menstrual Collective	Disability and Inclusion
WHO Global research	GeoPoll: SSA	Cambridge University Press	ODI	SLH: Handwashing in low resource settings	Coregroup IDDC
COVID-19 Solidarity Response Fund	Global Health Network Africa	Cell Press	Johns Hopkins University	RBM Partnership	Ethics, health systems & COVID-19
UN	African Academy of Sciences	Cochrane	Center for Global Development		Social Development Direct C19 blog series

UN Women	Africa Evidence Network	Elsevier	CMMID Repository		
UNOCHA	OCHA Southern and Eastern Africa COVID-19 Digest	JAMA Network	Norwegian Institute of Public Health		
UNHCR	South African Government	The Lancet	Oxford Centre for Evidence-based Medicine		
UNICEF		medRxiv and bioRxiv (Preprints)	HEART		
UNESCO		NEJM	UKRI		
UN WFP		Oxford University Press	Evidence Aid		
GOARN		PLoS	NIH		
EPI-WIN		SAGE journals	IFPRI Resources and Analyses of C19 Impact		
World Bank		Science	Prevent Epidemics		
Our World in Data		Springer Nature			
COVID-19 Narratives by David Nabarro		SSRN (Preprints)			

Reliefweb		Wiley			
Humanitarian OpenStreetMap Team					
Global Partnership for Sustainable Development Data					
WorldPop					
Flowminder					
COVID-END					
Premise COVID-19 Global Impact Study					

## Online learning & events

Date	Title/URL	Online learning/event	Duration	Lead
Available now	<a href="#">Standard precautions: Environmental cleaning and disinfection</a>	Online course	1 hour	WHO
16.06.2020	<a href="#">Africa beyond COVID-19</a>	Virtual event	1h 30 hours	ODI
15.06.2020	<a href="#">Poverty monitoring in the context of Covid-19</a>	Virtual event	1h 15	ODI

Available now	<a href="#">COVID-19: Effective Nursing in Times of Crisis</a>	Online course	2 weeks – 2 hours per week	Johns Hopkins School of Nursing
05.06.2020 12pm ET	<a href="#">CGD Conversations on COVID-19 and Development: John Nkengasong</a>	Event		CGD
Available now	<a href="#">WHO Academy and WHO Info mobile applications</a>	Mobile app		WHO
Available now	<a href="#">COVID-19: Pandemics, Modelling and Policy</a>	Online learning	2 weeks   2 hours weekly study	FutureLearn UNESCO UNITWIN Complex Systems Digital Campus/Open University
12.05.2020	<a href="#">COVID-19 and maintaining quality essential health services</a>	Webinar	1 hour	WHO & ISQua – Dr Shams Syed, Dr Peter Lachman, Dr Teri Rynolds & Dr Ed Kelley
11.5.2020	<a href="#">COVID-19 Contact Tracing course</a>	Online learning	5 hours	Johns Hopkins Bloomberg School of Health
7-28 May 2020	<a href="#">Virtual Evidence Weeks</a>	5 sessions	1h 30	International Initiative for Impact Evaluation (3ie)
Tuesdays at 1700 CEST (Geneva time) & Thursdays 0830 CEST (Geneva time)	<a href="#">COVID-19 Open online brief with Dr David Nabarro</a>	Event	1h	4SD

30.04.2020	Professor Chris Whitty's Gresham lecture on COVID-19	Event	1h 20	Gresham College
Available now	Emerging respiratory viruses, including COVID-19: methods for detection, prevention, response and control	Online learning	3 hours	WHO
Available now	Responding to COVID-19: Real-time training for the coronavirus disease outbreak	Online learning	Multiple self-paced course	WHO
25 May 2020	COVID-19: Tackling the Novel Coronavirus	Online learning	3 weeks   4 hours weekly study	FutureLearn LSHTM/UK PHRST
Available online now without mentors. Updated version will commence early June 2020	COVID-19 Diagnostics and Testing	Online learning	3 weeks   3 hours weekly study	FutureLearn FIND/LSHTM/ASLM
6 April 2020	COVID-19 Critical Care: Understanding and Application	Online learning	5 weeks   1 hour weekly study	FutureLearn University of Edinburgh & Royal College of Physicians of Edinburgh
Available now	COVID-19 supporting online courses	Online learning	Multiple self-paced course	BMJ Learning

## Suggested citation

Millington, K.A. and Reddin, S. (2020). *COVID-19 Health Evidence Summary No.56*. K4D Evidence Summary. Brighton, UK: Institute of Development Studies.

## Rapid review methodology

The rapid daily search for peer-reviewed literature is carried out through a PubMed search with the following keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa” OR “South Asia” OR “Developing” OR “low-income” OR “low income” OR “lower-middle income” OR “low and middle income” OR “LMIC” OR “LIC” OR “global south”) OR (“poverty”) OR (“equity” OR “equities”), restricted to articles published in the previous 2 to 3 days, in English. This is complemented by a search of the homepage of the following high-impact global health journals: The Lancet journals, New England Journal of Medicine, Nature, JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ Global Health, the PLoS journals and a Twitter search of their Twitter pages. A search also of preprints from bioRxiv and medRxiv. Please note that papers that have **not been peer-reviewed** are highlighted in red. All primary research papers that relate to the primary and secondary impacts of the COVID-19 response in LMICs, and disease control and health system responses are included. Articles related to tackling the secondary impacts on other sectors are not included. Additional commentaries, opinions, and commissioned pieces are selected based on relevance.

The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter.

## About this report

This is a weekly summary of the daily COVID-19 health evidence summary (HES) which are based on 3 hours of desk-based research each day. The summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make original documents easily accessible to decision makers which, if relevant to them, they should go to before making decisions. The HES are not intended to replace medical or professional advice and the researcher or the K4D consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES alone. K4D services are provided by a consortium of leading organisations working in international development, led by the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds Nuffield Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), University of Birmingham International Development Department (IDD) and the University of Manchester Humanitarian and Conflict Response Institute (HCRI).

This evidence summary was prepared for the UK Government’s Department for International Development (DFID) and its partners in support of pro-poor programmes. It is licensed for non-commercial purposes only. K4D cannot be held responsible for errors, omissions or any consequences arising from the use of information contained in this health evidence summary. Any views and opinions expressed do not necessarily reflect those of DFID, K4D or any other contributing organisation.



© DFID - Crown copyright 2020.